{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:43:32Z","timestamp":1792413812075,"version":"4.4.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41571-026-01198-z","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:17:07Z","timestamp":1788434227000},"page":"893-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-6821","authenticated-orcid":false,"given":"William","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-004X","authenticated-orcid":false,"given":"Howard L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-0113","authenticated-orcid":false,"given":"Robert L.","family":"Martuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1198_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 https:\/\/doi.org\/10.1056\/nejmoa1003466 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/nejmoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 https:\/\/doi.org\/10.1056\/nejmoa1503093 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. et al. The future of immune checkpoint therapy. Science 348, 56\u201361 https:\/\/doi.org\/10.1126\/science.aaa8172 (2015).","journal-title":"Science"},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/ijc.35347","volume":"156","author":"A Haslam","year":"2025","unstructured":"Haslam, A. et al. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Int. J. Cancer 156, 2352\u20132359 https:\/\/doi.org\/10.1002\/ijc.35347 (2025).","journal-title":"Int. J. Cancer"},{"key":"1198_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg, P. et al. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J. Clin. Med. 13, 6537 https:\/\/doi.org\/10.3390\/jcm13216537 (2024).","journal-title":"J. Clin. Med."},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 405, 839\u2013849 https:\/\/doi.org\/10.1016\/s0140-6736(24)02722-3 (2025).","journal-title":"Lancet"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/s1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao, X. et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 24, 1134\u20131146 https:\/\/doi.org\/10.1016\/s1470-2045(23)00411-4 (2023).","journal-title":"Lancet Oncol."},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 11, e38\u2013e50 https:\/\/doi.org\/10.1016\/S2352-3026(23)00333-2 (2024).","journal-title":"Lancet Haematol."},{"key":"1198_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT051","volume":"85","author":"S Peters","year":"2025","unstructured":"Peters, S. et al. SKYSCRAPER-01: a phase III, randomized trial of tiragolumab + atezolizumab versus placebo + atezolizumab in patients with previously-untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC [abstract]. Cancer Res. 85, CT051 https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT051 (2025).","journal-title":"Cancer Res."},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.medj.2024.02.001","volume":"5","author":"JC Laguna","year":"2024","unstructured":"Laguna, J. C. et al. Rethinking strategies in SCLC: lessons learned from tiragolumab in the SKYSCRAPER-02 study. Med 5, 281\u2013284 https:\/\/doi.org\/10.1016\/j.medj.2024.02.001 (2024).","journal-title":"Med"},{"key":"1198_CR11","unstructured":"Regeneron Pharmaceuticals. Regeneron provides update on phase 3 trial of fianlimab (LAG-3 inhibitor) combination in first-line unresectable or metastatic melanoma. GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2026\/05\/16\/3296192\/0\/en\/ Regeneron-Provides-Update-on-Phase-3-Trial-of-Fianlimab-LAG-3-Inhibitor -Combination-in-First-Line-Unresectable-or-Metastatic-Melanoma.html (2026)."},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 https:\/\/doi.org\/10.1056\/nejmoa2109970 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. et al. Elements of cancer immunity and the cancer\u2013immune set point. Nature 541, 321\u2013330 https:\/\/doi.org\/10.1038\/nature21349 (2017).","journal-title":"Nature"},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang, M. M. et al. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br. J. Cancer 129, 1212\u20131224 https:\/\/doi.org\/10.1038\/s41416-023-02361-4 (2023).","journal-title":"Br. J. Cancer"},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 https:\/\/doi.org\/10.1038\/nature13954 (2014).","journal-title":"Nature"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 https:\/\/doi.org\/10.1016\/j.cell.2017.01.017 (2017).","journal-title":"Cell"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. et al. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 https:\/\/doi.org\/10.1126\/science.aaa6204 (2015).","journal-title":"Science"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 https:\/\/doi.org\/10.1038\/nature25501 (2018).","journal-title":"Nature"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e10 https:\/\/doi.org\/10.1016\/j.cell.2017.08.027 (2017).","journal-title":"Cell"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly, E. et al. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651\u2013659 https:\/\/doi.org\/10.1038\/sj.mt.6300108 (2007).","journal-title":"Mol. Ther."},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey, M. C. et al. Reovirus therapy of tumors with activated ras pathway. Science 282, 1332\u20131334 https:\/\/doi.org\/10.1126\/science.282.5392.1332 (1998).","journal-title":"Science"},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373\u2013376 https:\/\/doi.org\/10.1126\/science.274.5286.373 (1996).","journal-title":"Science"},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821\u2013825 https:\/\/doi.org\/10.1038\/77558 (2000).","journal-title":"Nat. Med."},{"key":"1198_CR24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza, R. L. et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854\u2013856 https:\/\/doi.org\/10.1126\/science.1851332 (1991).","journal-title":"Science"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L. et al. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug. Discov. 14, 642\u2013662 https:\/\/doi.org\/10.1038\/nrd4663 (2015).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1198_CR26","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","volume":"160","author":"M Toda","year":"1998","unstructured":"Toda, M., Martuza, R. L., Kojima, H. & Rabkin, S. D. In situ cancer vaccination: an IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor immunity. J. Immunol. 160, 4457\u20134464 (1998).","journal-title":"J. Immunol."},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/10430349950018832","volume":"10","author":"M Toda","year":"1999","unstructured":"Toda, M., Rabkin, S. D., Kojima, H. & Martuza, R. L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10, 385\u2013393 (1999).","journal-title":"Hum. Gene Ther."},{"key":"1198_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641, 503\u2013511 https:\/\/doi.org\/10.1038\/s41586-025-08717-5 (2025).","journal-title":"Nature"},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/jco.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol. 41, 528\u2013540 https:\/\/doi.org\/10.1200\/jco.22.00343 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8110484","volume":"8","author":"DV Chouljenko","year":"2020","unstructured":"Chouljenko, D. V. et al. Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines 8, 484 https:\/\/doi.org\/10.3390\/biomedicines8110484 (2020).","journal-title":"Biomedicines"},{"key":"1198_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal. Transduct. Target. Ther. 7, 117 https:\/\/doi.org\/10.1038\/s41392-022-00951-x (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1198_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1226","volume":"9","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Therapeutic strategies to remodel immunologically cold tumors. Clin. Transl. Immunol. 9, e1226 https:\/\/doi.org\/10.1002\/cti2.1226 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan, Q. et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 6, 605\u2013618 https:\/\/doi.org\/10.1016\/j.trecan.2020.02.022 (2020).","journal-title":"Trends Cancer"},{"key":"1198_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103362","volume":"86","author":"P Lau","year":"2025","unstructured":"Lau, P. et al. Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis. eClinicalMedicine 86, 103362 https:\/\/doi.org\/10.1016\/j.eclinm.2025.103362 (2025).","journal-title":"eClinicalMedicine"},{"key":"1198_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1023533","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: a meta-analysis. Front. Pharmacol. 13, 1023533 https:\/\/doi.org\/10.3389\/fphar.2022.1023533 (2022).","journal-title":"Front. Pharmacol."},{"key":"1198_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/cmr.0000000000000180","volume":"25","author":"S Doni\u0146a","year":"2015","unstructured":"Doni\u0146a, S. et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 25, 421\u2013426 https:\/\/doi.org\/10.1097\/cmr.0000000000000180 (2015).","journal-title":"Melanoma Res."},{"key":"1198_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","volume":"837","author":"PT Alberts","year":"2018","unstructured":"Alberts, P. T. et al. The advent of oncolytic virotherapy in oncology: the Rigvir\u00ae story. Eur. J. Pharmacol. 837, 117\u2013126 https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.042 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"1198_CR38","unstructured":"State Agency of Medicines Republic of Latvia. Rigvir marketing authorisation suspended; information for current patients. State Agency of Medicines Republic of Latvia https:\/\/www.zva.gov.lv\/en\/news-and-publications\/news\/rigvir-marketing -authorisation-suspended-information-current- patients (2019)."},{"key":"1198_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug. Targets 18, 171\u2013176 https:\/\/doi.org\/10.2174\/1568009618666171129221503 (2018).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.ymthe.2024.04.029","volume":"32","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Oncolytic adenovirus in treating malignant ascites: a phase II trial and longitudinal single-cell study. Mol. Ther. 32, 2000\u20132020 https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.029 (2024).","journal-title":"Mol. Ther."},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. I. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J. Immunother. Cancer 7, 145 https:\/\/doi.org\/10.1186\/s40425-019-0623-z (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR42","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630\u20131639 https:\/\/doi.org\/10.1038\/s41591-022-01897-x (2022).","journal-title":"Nat. Med."},{"key":"1198_CR43","unstructured":"Pharma Japan. Japan approves Oncolys\u2019 Telomelysin for esophageal cancer. Pharma Japan https:\/\/pj.jiho.jp\/article\/255568 (2026)."},{"key":"1198_CR44","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg- combination-nivolumab-melanoma (2026)."},{"key":"1198_CR45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol. Ther. 24, 1150\u20131158 https:\/\/doi.org\/10.1038\/mt.2016.66 (2016).","journal-title":"Mol. Ther."},{"key":"1198_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-017-4538-4","volume":"167","author":"V Bernstein","year":"2018","unstructured":"Bernstein, V. et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian cancer trials group IND.213. Breast Cancer Res. Treat. 167, 485\u2013493 https:\/\/doi.org\/10.1007\/s10549-017-4538-4 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"1198_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9030","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I. et al. Final data from CALM: a phase II study of coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma [abstract]. J. Clin. Oncol. 33, 9030 https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.9030 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04695-1","volume":"24","author":"Ji","year":"2026","unstructured":"Ji et al. First-in-human phase 1\/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. BMC Med. 24, 177 https:\/\/doi.org\/10.1186\/s12916-026-04695-1 (2026).","journal-title":"BMC Med."},{"key":"1198_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000533650","volume":"13","author":"GK Abou-Alfa","year":"2023","unstructured":"Abou-Alfa, G. K. et al. PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer 13, 248\u2013264 https:\/\/doi.org\/10.1159\/000533650 (2023).","journal-title":"Liver Cancer"},{"key":"1198_CR50","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(26)00194-4","volume":"27","author":"MD Tyson","year":"2026","unstructured":"Tyson, M. D. et al. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. Lancet Oncol. 27, 983\u2013993 https:\/\/doi.org\/10.1016\/S1470-2045(26)00194-4 (2026).","journal-title":"Lancet Oncol."},{"key":"1198_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P343","volume":"3","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I. et al. Phase II CALM extension study: coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment [abstract]. J. Immunother. Cancer 3, P343 https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P343 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR52","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.ccr-25-1449","volume":"31","author":"A Balasubramanian","year":"2025","unstructured":"Balasubramanian, A. et al. Effects of CVA21, an oncolytic virus, in combination with pembrolizumab on immunogenicity and the tumor microenvironment in advanced NSCLC: a phase I\/II trial. Clin. Cancer Res. 31, 4644\u20134654 https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-1449 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR53","unstructured":"Bayer, M. Merck & Co. ditches oncolytic virus CAVATAK 4 years after buying viralytics. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/merck-ditches- cavatak-more-four-years-after-buying-viralytics (2022)"},{"key":"1198_CR54","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/gutjnl-2025-335904","volume":"75","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies. Gut 75, 588\u2013604 https:\/\/doi.org\/10.1136\/gutjnl-2025-335904 (2025).","journal-title":"Gut"},{"key":"1198_CR55","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1200\/jco-25-01346","volume":"43","author":"MK Wong","year":"2025","unstructured":"Wong, M. K. et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE). J. Clin. Oncol. 43, 3589\u20133599 https:\/\/doi.org\/10.1200\/jco-25-01346 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR56","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/jci82416","volume":"125","author":"CJ Cohen","year":"2015","unstructured":"Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981\u20133991 https:\/\/doi.org\/10.1172\/jci82416 (2015).","journal-title":"J. Clin. Invest."},{"key":"1198_CR57","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"R Yossef","year":"2023","unstructured":"Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in\u00a0patients with metastatic cancers. Cancer Cell 41, 2154\u20132165.e5 https:\/\/doi.org\/10.1016\/j.ccell.2023.11.005 (2023).","journal-title":"Cancer Cell"},{"key":"1198_CR58","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1182\/blood-2009-10-251124","volume":"115","author":"C Alanio","year":"2010","unstructured":"Alanio, C. et al. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 115, 3718\u20133725 https:\/\/doi.org\/10.1182\/blood-2009-10-251124 (2010).","journal-title":"Blood"},{"key":"1198_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012 (2013).","journal-title":"Immunity"},{"key":"1198_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau0417","volume":"10","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K. et al. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. 10, eaau0417 https:\/\/doi.org\/10.1126\/scitranslmed.aau0417 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1198_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004335","volume":"10","author":"JP van Vloten","year":"2022","unstructured":"van Vloten, J. P. et al. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J. Immunother. Cancer 10, e004335 https:\/\/doi.org\/10.1136\/jitc-2021-004335 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR62","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K. et al. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498\u2013513 https:\/\/doi.org\/10.1038\/s41577-018-0014-6 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1198_CR63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","volume":"33","author":"SJ Russell","year":"2018","unstructured":"Russell, S. J. & Barber, G. N. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33, 599\u2013605 https:\/\/doi.org\/10.1016\/j.ccell.2018.03.011 (2018).","journal-title":"Cancer Cell"},{"key":"1198_CR64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell. Mol. Immunol. 20, 432\u2013447 https:\/\/doi.org\/10.1038\/s41423-023-00990-6 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"1198_CR65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 https:\/\/doi.org\/10.1038\/s41571-024-00859-1 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1198_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.ccr-19-2078","volume":"26","author":"D Mahalingam","year":"2020","unstructured":"Mahalingam, D. et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ib study. Clin. Cancer Res. 26, 71\u201381 https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2078 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR67","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1158\/1535-7163.mct-20-0902","volume":"20","author":"J Harper","year":"2021","unstructured":"Harper, J. et al. Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. Mol. Cancer Ther. 20, 1723\u20131734 https:\/\/doi.org\/10.1158\/1535-7163.mct-20-0902 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1198_CR68","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 https:\/\/doi.org\/10.1126\/scitranslmed.3008095 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1198_CR69","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty, B. D. et al. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559\u2013567 https:\/\/doi.org\/10.1038\/nrc3770 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1198_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49286-x","volume":"15","author":"MJ Webb","year":"2024","unstructured":"Webb, M. J. et al. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Nat. Commun. 15, 5442 https:\/\/doi.org\/10.1038\/s41467-024-49286-x (2024).","journal-title":"Nat. Commun."},{"key":"1198_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34791-8","volume":"13","author":"J Svensson-Arvelund","year":"2022","unstructured":"Svensson-Arvelund, J. et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat. Commun. 13, 7149 https:\/\/doi.org\/10.1038\/s41467-022-34791-8 (2022).","journal-title":"Nat. Commun."},{"key":"1198_CR72","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.ccr-15-2667","volume":"22","author":"FJ Kohlhapp","year":"2016","unstructured":"Kohlhapp, F. J. et al. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 22, 1048\u20131054 https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2667 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR73","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1158\/0008-5472.can-04-0757","volume":"64","author":"P Serafini","year":"2004","unstructured":"Serafini, P. et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64, 6337\u20136343 https:\/\/doi.org\/10.1158\/0008-5472.can-04-0757 (2004).","journal-title":"Cancer Res."},{"key":"1198_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-009-0622-8","volume":"123","author":"JK Morales","year":"2010","unstructured":"Morales, J. K. et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123, 39\u201349 https:\/\/doi.org\/10.1007\/s10549-009-0622-8 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"1198_CR75","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3109\/08820139.2012.703745","volume":"41","author":"PA Cohen","year":"2012","unstructured":"Cohen, P. A. et al. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol. Invest. 41, 680\u2013710 https:\/\/doi.org\/10.3109\/08820139.2012.703745 (2012).","journal-title":"Immunol. Invest."},{"key":"1198_CR76","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 https:\/\/doi.org\/10.1038\/s41577-020-00490-y (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1198_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100729","volume":"31","author":"NI Khushalani","year":"2023","unstructured":"Khushalani, N. I. et al. Breaking the barriers in cancer care: the next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Mol. Ther. Oncolytics 31, 100729 https:\/\/doi.org\/10.1016\/j.omto.2023.100729 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1198_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 https:\/\/doi.org\/10.1038\/s41577-019-0210-z (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1198_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0952-7915(00)00180-1","volume":"13","author":"C Th\u00e9ry","year":"2001","unstructured":"Th\u00e9ry, C. et al. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 13, 45\u201351 https:\/\/doi.org\/10.1016\/s0952-7915(00)00180-1 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"1198_CR80","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S. et al. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 https:\/\/doi.org\/10.1038\/s41568-021-00339-z (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1198_CR81","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 https:\/\/doi.org\/10.1016\/j.ccell.2014.09.007 (2014).","journal-title":"Cancer Cell"},{"key":"1198_CR82","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 https:\/\/doi.org\/10.1016\/j.ccell.2016.06.003 (2016).","journal-title":"Cancer Cell"},{"key":"1198_CR83","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 https:\/\/doi.org\/10.1038\/s41586-020-2134-y (2020).","journal-title":"Nature"},{"key":"1198_CR84","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V. et al. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38, 454\u2013472 https:\/\/doi.org\/10.1016\/j.ccell.2020.07.013 (2020).","journal-title":"Cancer Cell"},{"key":"1198_CR85","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki, A. et al. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987\u2013995 https:\/\/doi.org\/10.1038\/ni1112 (2004).","journal-title":"Nat. Immunol."},{"key":"1198_CR86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki, A. et al. Regulation of adaptive immunity by the innate immune system. Science 327, 291\u2013295 https:\/\/doi.org\/10.1126\/science.1183021 (2010).","journal-title":"Science"},{"key":"1198_CR87","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger, S. P. et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions. Nature 393, 480\u2013483 https:\/\/doi.org\/10.1038\/31002 (1998).","journal-title":"Nature"},{"key":"1198_CR88","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ncb1552","volume":"9","author":"C Jancic","year":"2007","unstructured":"Jancic, C. et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat. Cell Biol. 9, 367\u2013378 https:\/\/doi.org\/10.1038\/ncb1552 (2007).","journal-title":"Nat. Cell Biol."},{"key":"1198_CR89","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1182\/blood-2008-01-134791","volume":"112","author":"AR Mantegazza","year":"2008","unstructured":"Mantegazza, A. R. et al. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood 112, 4712\u20134722 https:\/\/doi.org\/10.1182\/blood-2008-01-134791 (2008).","journal-title":"Blood"},{"key":"1198_CR90","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2014.04.054","volume":"158","author":"P Nair-Gupta","year":"2014","unstructured":"Nair-Gupta, P. et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. Cell 158, 506\u2013521 https:\/\/doi.org\/10.1016\/j.cell.2014.04.054 (2014).","journal-title":"Cell"},{"key":"1198_CR91","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49, 1148\u20131161 https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024 (2018).","journal-title":"Immunity"},{"key":"1198_CR92","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","volume":"162","author":"JM Curtsinger","year":"1999","unstructured":"Curtsinger, J. M. et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162, 3256\u20133262 (1999). PMID: 10092777.","journal-title":"J. Immunol."},{"key":"1198_CR93","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.20021910","volume":"197","author":"JM Curtsinger","year":"2003","unstructured":"Curtsinger, J. M., Lins, D. C. & Mescher, M. F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197, 1141\u20131151 https:\/\/doi.org\/10.1084\/jem.20021910 (2003).","journal-title":"J. Exp. Med."},{"key":"1198_CR94","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood-2005-03-1154","volume":"106","author":"T Walzer","year":"2005","unstructured":"Walzer, T. et al. Natural-killer cells and dendritic cells: \u201cl\u2019union fait la force\u201d. Blood 106, 2252\u20132258 https:\/\/doi.org\/10.1182\/blood-2005-03-1154 (2005).","journal-title":"Blood"},{"key":"1198_CR95","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois, S. et al. IL-15R\u03b1 recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537\u2013547 https:\/\/doi.org\/10.1016\/s1074-7613(02)00429-6 (2002).","journal-title":"Immunity"},{"key":"1198_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000599","volume":"8","author":"C Bergamaschi","year":"2020","unstructured":"Bergamaschi, C. et al. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10. J. Immunother. Cancer 8, e000599 https:\/\/doi.org\/10.1136\/jitc-2020-000599 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR97","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1182\/blood-2003-01-0183","volume":"102","author":"NL Alves","year":"2003","unstructured":"Alves, N. L. et al. IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood 102, 2541\u20132546 https:\/\/doi.org\/10.1182\/blood-2003-01-0183 (2003).","journal-title":"Blood"},{"key":"1198_CR98","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.20010938","volume":"195","author":"F Gerosa","year":"2002","unstructured":"Gerosa, F. et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195, 327\u2013333 https:\/\/doi.org\/10.1084\/jem.20010938 (2002).","journal-title":"J. Exp. Med."},{"key":"1198_CR99","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s1074-7613(03)00264-4","volume":"19","author":"R Mocikat","year":"2003","unstructured":"Mocikat, R. et al. Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561\u2013569 https:\/\/doi.org\/10.1016\/s1074-7613(03)00264-4 (2003).","journal-title":"Immunity"},{"key":"1198_CR100","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2023","unstructured":"Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240\u2013261 https:\/\/doi.org\/10.1038\/s43018-023-00668-y (2023).","journal-title":"Nat. Cancer"},{"key":"1198_CR101","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri1549","volume":"5","author":"MA Degli-Esposti","year":"2005","unstructured":"Degli-Esposti, M. A. et al. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5, 112\u2013124 https:\/\/doi.org\/10.1038\/nri1549 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"1198_CR102","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/ijc.22279","volume":"119","author":"A Capobianco","year":"2006","unstructured":"Capobianco, A. et al. Melanoma cells interfere with the interaction of dendritic cells with NK\/LAK cells. Int. J. Cancer 119, 2861\u20132869 https:\/\/doi.org\/10.1002\/ijc.22279 (2006).","journal-title":"Int. J. Cancer"},{"key":"1198_CR103","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 https:\/\/doi.org\/10.1084\/jem.20101159 (2011).","journal-title":"J. Exp. Med."},{"key":"1198_CR104","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 https:\/\/doi.org\/10.1016\/j.immuni.2014.10.017 (2014).","journal-title":"Immunity"},{"key":"1198_CR105","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1512329","volume":"8","author":"JG Pol","year":"2019","unstructured":"Pol, J. G. et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology 8, e1512329 https:\/\/doi.org\/10.1080\/2162402x.2018.1512329 (2019).","journal-title":"Oncoimmunology"},{"key":"1198_CR106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.e14637","volume":"35","author":"DJ Jonker","year":"2017","unstructured":"Jonker, D. J. et al. Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214 [abstract]. J. Clin. Oncol. 35, e14637 https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.e14637 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR107","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. et al. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 https:\/\/doi.org\/10.1038\/s41571-020-00460-2 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1198_CR108","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","volume":"188","author":"L Zhong","year":"2025","unstructured":"Zhong, L. et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell 188, 1119\u20131136.e23 https:\/\/doi.org\/10.1016\/j.cell.2024.12.010 (2025).","journal-title":"Cell"},{"key":"1198_CR109","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/10430342261423100","volume":"37","author":"X Zhang","year":"2026","unstructured":"Zhang, X. et al. Construct optimization enables oncolytic virus-mediated functional membrane localization of calreticulin and macrophage reprogramming. Hum. Gene Ther. 37, 412\u2013424 https:\/\/doi.org\/10.1177\/10430342261423100 (2026).","journal-title":"Hum. Gene Ther."},{"key":"1198_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.115174","volume":"29","author":"L Pan","year":"2026","unstructured":"Pan, L. et al. An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma. iScience 29, 115174 https:\/\/doi.org\/10.1016\/j.isci.2026.115174 (2026).","journal-title":"iScience"},{"key":"1198_CR111","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser, S. et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186\u20131190 https:\/\/doi.org\/10.1038\/nature03884 (2005).","journal-title":"Nature"},{"key":"1198_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231782","volume":"14","author":"R Khaleafi","year":"2023","unstructured":"Khaleafi, R. et al. Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality. Front. Immunol. 14, 1231782 https:\/\/doi.org\/10.3389\/fimmu.2023.1231782 (2023).","journal-title":"Front. Immunol."},{"key":"1198_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/v14112327","volume":"14","author":"J Ding","year":"2022","unstructured":"Ding, J. et al. Pre-existing HSV-1 immunity enhances anticancer efficacy of a novel immune-stimulating oncolytic virus. Viruses 14, 2327 https:\/\/doi.org\/10.3390\/v14112327 (2022).","journal-title":"Viruses"},{"key":"1198_CR114","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157\u2013166 https:\/\/doi.org\/10.1038\/s41586-023-06623-2 (2023).","journal-title":"Nature"},{"key":"1198_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","volume":"70","author":"C Groeneveldt","year":"2023","unstructured":"Groeneveldt, C. et al. Preexisting immunity: barrier or bridge to effective oncolytic virus therapy? Cytokine Growth Factor Rev. 70, 1\u201312 https:\/\/doi.org\/10.1016\/j.cytogfr.2023.01.002 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1198_CR116","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","volume":"26","author":"JM Ricca","year":"2018","unstructured":"Ricca, J. M. et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol. Ther. 26, 1008\u20131019 https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.019 (2018).","journal-title":"Mol. Ther."},{"key":"1198_CR117","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1198_CR118","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug. Discov. 18, 689\u2013706 https:\/\/doi.org\/10.1038\/s41573-019-0029-0 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1198_CR119","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 https:\/\/doi.org\/10.1016\/s1470-2045(17)30074-8 (2017).","journal-title":"Lancet Oncol."},{"key":"1198_CR120","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RHI Andtbacka","year":"2016","unstructured":"Andtbacka, R. H. I. et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23, 4169\u20134177 https:\/\/doi.org\/10.1245\/s10434-016-5286-0 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"1198_CR121","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/imm.13777","volume":"172","author":"X Li","year":"2024","unstructured":"Li, X. et al. Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen. Immunology 172, 375\u2013391 https:\/\/doi.org\/10.1111\/imm.13777 (2024).","journal-title":"Immunology"},{"key":"1198_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.629722","volume":"11","author":"SI Kim","year":"2021","unstructured":"Kim, S. I. et al. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front. Immunol. 11, 629722 https:\/\/doi.org\/10.3389\/fimmu.2020.629722 (2021).","journal-title":"Front. Immunol."},{"key":"1198_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030714","volume":"12","author":"JP Nesseler","year":"2020","unstructured":"Nesseler, J. P. et al. Tumor size matters \u2014 understanding concomitant tumor immunity in the context of hypofractionated radiotherapy with immunotherapy. Cancers 12, 714 https:\/\/doi.org\/10.3390\/cancers12030714 (2020).","journal-title":"Cancers"},{"key":"1198_CR124","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S. et al. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 https:\/\/doi.org\/10.1038\/s41571-018-0142-8 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1198_CR125","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903\u2013907 https:\/\/doi.org\/10.1038\/nature06309 (2007).","journal-title":"Nature"},{"key":"1198_CR126","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. et al. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 https:\/\/doi.org\/10.1055\/s-0030-1247132 (2010).","journal-title":"Semin. Liver Dis."},{"key":"1198_CR127","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","volume":"33","author":"J Luo","year":"2022","unstructured":"Luo, J. et al. Deciphering radiological stable disease to immune checkpoint inhibitors. Ann. Oncol. 33, 824\u2013835 https:\/\/doi.org\/10.1016\/j.annonc.2022.04.450 (2022).","journal-title":"Ann. Oncol."},{"key":"1198_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54945-6","volume":"14","author":"L Huang","year":"2024","unstructured":"Huang, L., Kang, D., Zhao, C. & Liu, X. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Sci. Rep. 14, 4327 https:\/\/doi.org\/10.1038\/s41598-024-54945-6 (2024).","journal-title":"Sci. Rep."},{"key":"1198_CR129","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00262-016-1854-1","volume":"65","author":"DD Stenehjem","year":"2016","unstructured":"Stenehjem, D. D. et al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol. Immunother. 65, 941\u2013949 https:\/\/doi.org\/10.1007\/s00262-016-1854-1 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"1198_CR130","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/jco.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse, D. M. et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J. Clin. Oncol. 38, 3863\u20133873 https:\/\/doi.org\/10.1200\/jco.20.00131 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR131","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/s1470-2045(19)30407-3","volume":"20","author":"SJ Antonia","year":"2019","unstructured":"Antonia, S. J. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 20, 1395\u20131408 https:\/\/doi.org\/10.1016\/s1470-2045(19)30407-3 (2019).","journal-title":"Lancet Oncol."},{"key":"1198_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030495","volume":"17","author":"A Jain","year":"2025","unstructured":"Jain, A. & Stebbing, J. The relationship between response rate and survival benefits in randomized immunotherapy studies. Cancers 17, 495 https:\/\/doi.org\/10.3390\/cancers17030495 (2025).","journal-title":"Cancers"},{"key":"1198_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105092","volume":"218","author":"F Salomone","year":"2026","unstructured":"Salomone, F. et al. Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 218, 105092 https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105092 (2026).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1198_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13712-0","volume":"25","author":"J Li","year":"2025","unstructured":"Li, J. et al. Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review. BMC Cancer 25, 293 https:\/\/doi.org\/10.1186\/s12885-025-13712-0 (2025).","journal-title":"BMC Cancer"},{"key":"1198_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10046-z","volume":"22","author":"T Hua","year":"2022","unstructured":"Hua, T., Gao, Y., Zhang, R., Wei, Y. & Chen, F. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer 22, 1022 https:\/\/doi.org\/10.1186\/s12885-022-10046-z (2022).","journal-title":"BMC Cancer"},{"key":"1198_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0276-8","volume":"5","author":"HL Kaufman","year":"2017","unstructured":"Kaufman, H. L. et al. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J. Immunother. Cancer 5, 72 https:\/\/doi.org\/10.1186\/s40425-017-0276-8 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR137","unstructured":"Center for Biologics Evaluation and Research. Complete Response Letter, Biologics License Application 125827 (vusolimogene oderparepvec in combination with nivolumab). FDA https:\/\/download.open.fda.gov\/crl\/CRL_BLA125827_20250721.pdf (2025)."},{"key":"1198_CR138","unstructured":"Center for Biologics Evaluation and Research. Complete Response Letter, Biologics License Application 125827 (vusolimogene oderparepvec in combination with nivolumab). FDA https:\/\/download.open.fda.gov\/crl\/CRL_BLA125827_20260410.pdf (2026)."},{"key":"1198_CR139","unstructured":"Center for Biologics Evaluation and Research. Cellular, Tissue, and Gene Therapies Advisory Committee Meeting Briefing Document, BLA 125827 (vusolimogene oderparepvec). FDA https:\/\/www.fda.gov\/media\/193878\/download (2026)."},{"key":"1198_CR140","unstructured":"Ryan, C. FDA CTGTAC votes in favor of RP1\/nivolumab data in advanced melanoma. OncLive https:\/\/www.onclive.com\/view\/fda-ctgtac-ignyte-data-rp1-nivolumab-advanced-melanoma (2026)."},{"key":"1198_CR141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9537","volume":"43","author":"GK In","year":"2025","unstructured":"In, G. K. Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep\/visceral RP1 injection in the registrational cohort of anti\u2013PD-1\u2013failed melanoma patients of the IGNYTE trial [abstract]. J. Clin. Oncol. 43, 9537 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9537 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR142","unstructured":"Rao, G. R. The FDA AdComm reboot: part 2; lessons from the meeting on Replimune\u2019s RP1. FDA Law Blog https:\/\/www.thefdalawblog.com\/2026\/08\/the-fda-adcomm-reboot -part-2-lessons-from-the-meeting-on-replimunes-rp1\/ (2026)."},{"key":"1198_CR143","unstructured":"Incorvaia, D. Replimune\u2019s twice-rejected melanoma drug prevails in FDA adcomm. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/replimunes-twice-rejected -melanoma-drug-prevails-fda-adcomm (2026)."},{"key":"1198_CR144","unstructured":"Gardner, J. Replimune melanoma drug wins support of FDA panel. BioPharma Dive https:\/\/www.biopharmadive.com\/news\/replimune-rp1-fda-vote-advisory -committee-melanoma-drug\/826619\/ (2026)."},{"key":"1198_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait, M. et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur. J. Cancer 88, 38\u201347 https:\/\/doi.org\/10.1016\/j.ejca.2017.10.017 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1198_CR146","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809342","volume":"10","author":"KI Jones","year":"2018","unstructured":"Jones, K. I. et al. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol. Med. 10, e9342 https:\/\/doi.org\/10.15252\/emmm.201809342 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1198_CR147","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","volume":"42","author":"IM Launonen","year":"2024","unstructured":"Launonen, I. M. et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell 42, 2045\u20132063.e10 https:\/\/doi.org\/10.1016\/j.ccell.2024.11.005 (2024).","journal-title":"Cancer Cell"},{"key":"1198_CR148","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/ijc.32191","volume":"145","author":"Y Jia","year":"2019","unstructured":"Jia, Y. et al. EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies. Int. J. Cancer 145, 1432\u20131444 https:\/\/doi.org\/10.1002\/ijc.32191 (2019).","journal-title":"Int. J. Cancer"},{"key":"1198_CR149","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M. et al. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 https:\/\/doi.org\/10.1038\/s41568-021-00346-0 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1198_CR150","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2533488","volume":"14","author":"O Kepp","year":"2025","unstructured":"Kepp, O. & Kroemer, G. Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody\u2013drug conjugates. Oncoimmunology 14, 2533488 https:\/\/doi.org\/10.1080\/2162402X.2025.2533488 (2025).","journal-title":"Oncoimmunology"},{"key":"1198_CR151","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/abt\/tbaf017","volume":"8","author":"L Yin","year":"2025","unstructured":"Yin, L. et al. Reprogramming the tumor microenvironment: synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors. Antib. Ther. 8, 262\u2013274 https:\/\/doi.org\/10.1093\/abt\/tbaf017 (2025).","journal-title":"Antib. Ther."},{"key":"1198_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang, K. et al. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front. Immunol. 14, 1045024 https:\/\/doi.org\/10.3389\/fimmu.2023.1045024 (2023).","journal-title":"Front. Immunol."},{"key":"1198_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1755512","volume":"17","author":"K Muthughavi","year":"2026","unstructured":"Muthughavi, K. et al. T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. Front. Immunol. 17, 1755512 https:\/\/doi.org\/10.3389\/fimmu.2026.1755512 (2026).","journal-title":"Front. Immunol."},{"key":"1198_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"U Dafni","year":"2021","unstructured":"Dafni, U. et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer 9, e002723 https:\/\/doi.org\/10.1136\/jitc-2021-002723 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR155","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G. et al. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008 (2017).","journal-title":"Cancer Cell"},{"key":"1198_CR156","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. et al. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 https:\/\/doi.org\/10.1126\/science.aaa4971 (2015).","journal-title":"Science"},{"key":"1198_CR157","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1002\/ijc.32612","volume":"145","author":"D Bassan","year":"2019","unstructured":"Bassan, D. et al. Optimizing T-cell receptor avidity with somatic hypermutation. Int. J. Cancer 145, 2816\u20132826 https:\/\/doi.org\/10.1002\/ijc.32612 (2019).","journal-title":"Int. J. Cancer"},{"key":"1198_CR158","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z. et al. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 https:\/\/doi.org\/10.1038\/s41571-022-00719-w (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1198_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00763-y","volume":"24","author":"GG Bitar","year":"2024","unstructured":"Bitar, G. G. et al. Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations. Cancer Imaging 24, 145 https:\/\/doi.org\/10.1186\/s40644-024-00763-y (2024).","journal-title":"Cancer Imaging"},{"key":"1198_CR160","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-020-00554-8","volume":"21","author":"CA Larocca","year":"2020","unstructured":"Larocca, C. A. et al. An update on the role of talimogene laherparepvec (T-VEC) in the treatment of melanoma: best practices and future directions. Am. J. Clin. Dermatol. 21, 821\u2013832 https:\/\/doi.org\/10.1007\/s40257-020-00554-8 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1198_CR161","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan, R. et al. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28, 285\u2013295 https:\/\/doi.org\/10.1016\/j.ccell.2015.08.004 (2015).","journal-title":"Cancer Cell"},{"key":"1198_CR162","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/jco.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658\u20131667 https:\/\/doi.org\/10.1200\/jco.2017.73.7379 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR163","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006270","volume":"11","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J. Immunother. Cancer 11, e006270 https:\/\/doi.org\/10.1136\/jitc-2022-006270 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR164","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/nejmoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman, G. K. et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N. Engl. J. Med. 384, 1613\u20131622 https:\/\/doi.org\/10.1056\/nejmoa2024947 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR165","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003119","volume":"9","author":"V Monga","year":"2021","unstructured":"Monga, V. et al. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB\/II trial. J. Immunother. Cancer 9, e003119 https:\/\/doi.org\/10.1136\/jitc-2021-003119 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR166","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ijrobp.2023.08.044","volume":"118","author":"J Guan","year":"2024","unstructured":"Guan, J. et al. A phase 2 study of in situ oncolytic virus therapy and stereotactic body radiation therapy followed by pembrolizumab in metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 118, 1531\u20131540 https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.044 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1198_CR167","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.ccr-16-3232","volume":"23","author":"LK Mell","year":"2017","unstructured":"Mell, L. K. et al. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin. Cancer Res. 23, 5696\u20135702 https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-3232 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR168","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1074-7613(02)00365-5","volume":"17","author":"S Jung","year":"2002","unstructured":"Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211\u2013220 https:\/\/doi.org\/10.1016\/S1074-7613(02)00365-5 (2002).","journal-title":"Immunity"},{"key":"1198_CR169","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02210-0","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat. Med. 29, 450\u2013457 https:\/\/doi.org\/10.1038\/s41591-023-02210-0 (2023).","journal-title":"Nat. Med."},{"key":"1198_CR170","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641\u2013648 https:\/\/doi.org\/10.1007\/s00262-006-0225-8 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"1198_CR171","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.ccr-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki, E. et al. Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713\u20136721 https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0883 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1071751","volume":"13","author":"S Mansouri","year":"2023","unstructured":"Mansouri, S. et al. Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. Front. Oncol. 13, 1071751 https:\/\/doi.org\/10.3389\/fonc.2023.1071751 (2023).","journal-title":"Front. Oncol."},{"key":"1198_CR173","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","volume":"86","author":"X Cheng","year":"2022","unstructured":"Cheng, X. et al. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin. Cancer Biol. 86, 408\u2013419 https:\/\/doi.org\/10.1016\/j.semcancer.2022.01.006 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1198_CR174","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrclinonc.2014.224","volume":"12","author":"M Horowitz","year":"2015","unstructured":"Horowitz, M. et al. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 12, 213\u2013226 https:\/\/doi.org\/10.1038\/nrclinonc.2014.224 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1198_CR175","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","volume":"10","author":"MC Bourgeois-Daigneault","year":"2018","unstructured":"Bourgeois-Daigneault, M. C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med. 10, eaao1641 https:\/\/doi.org\/10.1126\/scitranslmed.aao1641 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1198_CR176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000415","volume":"8","author":"J Ahmed","year":"2020","unstructured":"Ahmed, J. et al. A new oncolytic vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery. J. Immunother. Cancer 8, e000415 https:\/\/doi.org\/10.1136\/jitc-2019-000415 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00217","volume":"4","author":"LH Tai","year":"2014","unstructured":"Tai, L. H. et al. Attacking postoperative metastases using perioperative oncolytic viruses and viral vaccines. Front. Oncol. 4, 217 https:\/\/doi.org\/10.3389\/fonc.2014.00217 (2014).","journal-title":"Front. Oncol."},{"key":"1198_CR178","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","volume":"28","author":"B Philbrick","year":"2019","unstructured":"Philbrick, B. et al. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Expert. Opin. Investig. Drugs 28, 1041\u20131049 https:\/\/doi.org\/10.1080\/13543784.2019.1694000 (2019).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1198_CR179","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 https:\/\/doi.org\/10.1016\/s0140-6736(23)02268-7 (2024).","journal-title":"Lancet"},{"key":"1198_CR180","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1158\/1078-0432.ccr-12-1182","volume":"18","author":"A Cai","year":"2012","unstructured":"Cai, A. et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin. Cancer Res. 18, 5761\u20135772 https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-1182 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413521","volume":"22","author":"C Gentile","year":"2021","unstructured":"Gentile, C. et al. Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance. Int. J. Mol. Sci. 22, 13521 https:\/\/doi.org\/10.3390\/ijms222413521 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1198_CR182","doi-asserted-by":"publisher","first-page":"138ra77","DOI":"10.1126\/scitranslmed.3003578","volume":"4","author":"RA Adair","year":"2012","unstructured":"Adair, R. A. et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Transl. Med. 4, 138ra77 https:\/\/doi.org\/10.1126\/scitranslmed.3003578 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1198_CR183","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1158\/1078-0432.ccr-24-2701","volume":"31","author":"AS Clark","year":"2025","unstructured":"Clark, A. S. et al. A phase II randomized study of paclitaxel alone or combined with pelareorep with or without avelumab in metastatic hormone receptor-positive breast cancer: the BRACELET-01\/PrE0113 study. Clin. Cancer Res. 31, 2655\u20132662 https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-2701 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR184","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/leu.2017.120","volume":"31","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791\u20132798 https:\/\/doi.org\/10.1038\/leu.2017.120 (2017).","journal-title":"Leukemia"},{"key":"1198_CR185","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99\u2013102 https:\/\/doi.org\/10.1038\/nature10358 (2011).","journal-title":"Nature"},{"key":"1198_CR186","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/mt.2015.109","volume":"23","author":"SH Park","year":"2015","unstructured":"Park, S. H. et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in colorectal cancer. Mol. Ther. 23, 1532\u20131540 https:\/\/doi.org\/10.1038\/mt.2015.109 (2015).","journal-title":"Mol. Ther."},{"key":"1198_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1726128","volume":"16","author":"SS Raman","year":"2026","unstructured":"Raman, S. S. et al. Advancements in intratumoral therapies for liver tumors. Front. Oncol. 16, 1726128 https:\/\/doi.org\/10.3389\/fonc.2026.1726128 (2026).","journal-title":"Front. Oncol."},{"key":"1198_CR188","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/s1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533\u2013542 https:\/\/doi.org\/10.1016\/s1470-2045(08)70107-4 (2008).","journal-title":"Lancet Oncol."},{"key":"1198_CR189","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1158\/1078-0432.CCR-03-0123","volume":"9","author":"D Makower","year":"2003","unstructured":"Makower, D. et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 9, 693\u2013702 https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0123 (2003).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR190","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.2597","volume":"44","author":"C Robert","year":"2026","unstructured":"Robert, C. et al. Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases [abstract]. J. Clin. Oncol. 44, 2597 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2597 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR191","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/1078-0432.ccr-16-2900","volume":"23","author":"KA Streby","year":"2017","unstructured":"Streby, K. A. et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin. Cancer Res. 23, 3566\u20133574 https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2900 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1198_CR192","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486","volume":"8","author":"N Macedo","year":"2020","unstructured":"Macedo, N. et al. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer 8, e001486 https:\/\/doi.org\/10.1136\/jitc-2020-001486 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1198_CR193","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.7150\/thno.40902","volume":"10","author":"P Brugada-Vil\u00e0","year":"2020","unstructured":"Brugada-Vil\u00e0, P. et al. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics 10, 2744\u20132758 https:\/\/doi.org\/10.7150\/thno.40902 (2020).","journal-title":"Theranostics"},{"key":"1198_CR194","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01012-0","volume":"21","author":"N Ghasemi Darestani","year":"2023","unstructured":"Ghasemi Darestani, N. et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun. Signal. 21, 43 https:\/\/doi.org\/10.1186\/s12964-022-01012-0 (2023).","journal-title":"Cell Commun. Signal."},{"key":"1198_CR195","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ijc.28450","volume":"134","author":"VA Jennings","year":"2014","unstructured":"Jennings, V. A. et al. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int. J. Cancer 134, 1091\u20131101 https:\/\/doi.org\/10.1002\/ijc.28450 (2014).","journal-title":"Int. J. Cancer"},{"key":"1198_CR196","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/156800907780058880","volume":"7","author":"J Hardcastle","year":"2007","unstructured":"Hardcastle, J. et al. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug. Targets 7, 181\u2013189 https:\/\/doi.org\/10.2174\/156800907780058880 (2007).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"1198_CR197","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omto.2023.02.003","volume":"28","author":"DV Chouljenko","year":"2023","unstructured":"Chouljenko, D. V. et al. Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. Mol. Ther. Oncolytics 28, 334\u2013348 https:\/\/doi.org\/10.1016\/j.omto.2023.02.003 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1198_CR198","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.e15726","volume":"37","author":"C Fountzilas","year":"2019","unstructured":"Fountzilas, C. et al. Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC) [abstract]. J. Clin. Oncol. 37, e15726 https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.e15726 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1198_CR199","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873\u2013881 https:\/\/doi.org\/10.1038\/s43018-020-0096-5 (2020).","journal-title":"Nat. Cancer"},{"key":"1198_CR200","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00718","volume":"8","author":"H Ding","year":"2024","unstructured":"Ding, H. et al. Improving prediction of survival and progression in metastatic non-small cell lung cancer after immunotherapy through machine learning of circulating tumor DNA. JCO Precis. Oncol. 8, e2300718 https:\/\/doi.org\/10.1200\/po.23.00718 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1198_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113372","volume":"195","author":"N Honor\u00e9","year":"2023","unstructured":"Honor\u00e9, N. et al. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and\/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor. Eur. J. Cancer 195, 113372 https:\/\/doi.org\/10.1016\/j.ejca.2023.113372 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1198_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1678068","volume":"15","author":"QS Du","year":"2025","unstructured":"Du, Q. S. et al. Circulating free DNA as a predictive biomarker for response to nivolumab and platinum-based chemotherapy in metastatic esophageal adenocarcinoma: a prospective pilot study. Front. Oncol. 15, 1678068 https:\/\/doi.org\/10.3389\/fonc.2025.1678068 (2025).","journal-title":"Front. Oncol."},{"key":"1198_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104176","volume":"105","author":"C Evrard","year":"2025","unstructured":"Evrard, C. et al. Prognostic and predictive value of microsatellite instability analysis in circulating tumor DNA using digital droplet PCR for patients with microsatellite instability colorectal cancers. Lab. Invest. 105, 104176 https:\/\/doi.org\/10.1016\/j.labinv.2025.104176 (2025).","journal-title":"Lab. Invest."},{"key":"1198_CR204","unstructured":"Oncology Center for Excellence. Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; guidance for industry; availability. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use- circulating-tumor-deoxyribonucleic-acid-early-stage- solid-tumor -drug-development-guidance (2024)."},{"key":"1198_CR205","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442 (2018).","journal-title":"Cancer Discov."}],"updated-by":[{"DOI":"10.1038\/s41571-026-01205-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01198-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:03:05Z","timestamp":1792411385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01198-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":205,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01198-z","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"10 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-026-01205-3","URL":"https:\/\/doi.org\/10.1038\/s41571-026-01205-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.J. and R.Z. are Chief Scientific Officer and Chief Medical Officer, respectively, of Virogin Biotech, a company focusing on oncolytic virotherapy. H.L.K. is the President and Chief Executive Officer of Ankyra Therapeutics, an immunotherapy company. R.L.M. holds stock options in Virogin Biotech from a prior position on the Scientific Advisory Board.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}